We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Byotrol Plc | LSE:BYOT | London | Ordinary Share | GB00B0999995 | ORDS 0.01P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.10 | 0.05 | 0.15 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Chemicals & Chem Preps, Nec | 3.97M | -3.06M | -0.0068 | -0.15 | 453.89k |
TIDMBYOT
RNS Number : 4973A
Byotrol PLC
24 May 2023
Byotrol Plc
("Byotrol" or the "Company")
Director Dealing
Byotrol Plc (AIM: BYOT), the specialist infection prevention and control company, announces that on the 22(nd) of May 2023, the wife of Vivan Pinto, CEO of the Company, purchased a total of 500,000 ordinary shares of 0.25p each ("Ordinary Shares") at an average price of 1.60p per Ordinary Share (the "Purchase").
Following the Purchase, Vivan Pinto's beneficial holding (including those held by his wife) is 2,500,000 Ordinary Shares, representing 0.55% of the total voting rights of the Company. As announced on 28 July 2022, Vivan Pinto subscribed for convertible loan notes in the Company, which if converted would represent an additional 0.7% of the total voting rights of the Company.
For further information contact:
Byotrol Plc Trevor Francis, Non-Executive Chairman +44 (0)1925 742 000 Vivan Pinto, Chief Executive Officer Chris Sedwell, Chief Financial Officer finnCap Limited (Nominated Adviser and Broker) +44 (0)20 7220 0500 Geoff Nash / George Dollemore - Corporate Finance Nigel Birks / Harriet Ward - ECM Flagstaff Strategic and Investor Communications +44 (0)20 7129 1474 Tim Thompson/Andrea Seymour/Fergus Mellon byotrol@flagstaffcomms.com
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
Notes to editors
Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.
Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.
Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.
For more information, go to byotrol.com
The Notification of Dealing Form set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
1. Details of the person discharging managerial responsibilities / person closely associated a) Name Vivan Pinto ------------------------------- ---------------------------------- 2. Reason for the Notification ------------------------------------------------------------------- a) Position/status Chief Executive Officer ------------------------------- ---------------------------------- b) Initial notification/Amendment Initial Notification ------------------------------- ---------------------------------- 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ------------------------------------------------------------------- a) Name Byotrol plc ------------------------------- ---------------------------------- b) LEI 213800AJMTSTIPA59A34 ------------------------------- ---------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------- a) Description of the Ordinary shares of 0.25 pence per Financial instrument, share type of instrument ------------------------------- ---------------------------------- Identification code GB00B0999995 ------------------------------- ---------------------------------- b) Nature of the transaction Purchase of Ordinary Shares ------------------------------- ---------------------------------- c) Price(s) and volume(s) Price(s) Volume(s) 1.60p 500,000 ---------- ------------------------------- ---------------------------------- d) Aggregated information: * Aggregated volume See 4c) above * Price ------------------------------- ---------------------------------- e) Date of the transaction 22 May 2023 ------------------------------- ---------------------------------- f) Place of the transaction AIM, London Stock Exchange (XLON) ------------------------------- ----------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHDZGZKNDRGFZG
(END) Dow Jones Newswires
May 24, 2023 03:51 ET (07:51 GMT)
1 Year Byotrol Chart |
1 Month Byotrol Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions